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Abstract Recent studies demonstrate a role for intracellular
oxidation in the regulation of neutral sphingomyelinase
(N-SMase). Glutathione (GSH) has been shown to regulate
N-SMase in vitro and in cells. However, it has not been estab-
lished whether the e¡ects of GSH in cells are due to direct
action on N-SMase. In this study, treatment of human mam-
mary carcinoma MCF-7 cells with diamide, a thiol-depleting
agent, caused a decrease in intracellular GSH and degradation
of sphingomyelin (SM) to ceramide. The SM pool hydrolyzed in
response to diamide belonged to the bacterial SMase-resistant
pool of SM. Importantly, pretreatment of MCF-7 cells with
GSH, N-acetylcysteine, an antioxidant, or GW69A, a speci¢c
N-SMase inhibitor, prevented diamide-induced degradation of
SM to ceramide, suggesting that intracellular levels of GSH
regulate the extent to which SM is degraded to ceramide and
that this probably involves a GW69A-sensitive N-SMase. Un-
expectedly, expression of Bcl-xL prevented tumor necrosis fac-
tor-K-induced SM hydrolysis and ceramide accumulation but
not the decrease in intracellular GSH. Furthermore, Bcl-xL
inhibited diamide-induced SM hydrolysis and ceramide accumu-
lation but not the decrease in intracellular GSH. These results
suggest that the site of action of Bcl-xL is downstream of GSH
depletion and upstream of ceramide accumulation, and that
GSH probably does not exert direct physiologic e¡ects on
N-SMase.
1 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Sphingomyelinase (SMase) hydrolyzes sphingomyelin (SM)
to generate ceramide and phosphocholine, and several SMase
isoforms have been described [1]. In particular, acid SMase
(A-SMase) and neutral SMase (N-SMase) have been studied
in detail, and both A-SMase and N-SMase are activated in
response to cytokines and other agents [2^9].
Compared with A-SMase, the physiological function and
the regulatory mechanism of N-SMase remain rather elusive.
In spite of di⁄culties in its identi¢cation, there is evidence to
support the role of various factors that can regulate N-SMase,
especially glutathione (GSH) [10^12]. Recent studies have
demonstrated a link between GSH and the breakdown of
SM to ceramide based on the use of GSH precursors or
GSH-depleting agents [5,13^24]. Furthermore, overexpression
of GSH peroxidase-1 prevented activation of N-SMase, SM
hydrolysis, and ceramide generation in response to doxorubi-
cin [25]. These results suggest that the N-SMase/ceramide
pathway and intracellular oxidation are closely linked and
that intracellular GSH depletion might be upstream of
N-SMase activation. Recently, GSH was shown to inhibit
the activation of N-SMase in partially puri¢ed preparations.
However, there is no evidence to support a direct physiologic
e¡ect of GSH on N-SMase.
Members of the Bcl-2 family of proteins, which play an
important role in the regulation of apoptosis [26], have been
shown to inhibit ceramide-induced apoptosis and ceramide
accumulation [27^29]. Overexpression of Bcl-2 in MCF-7 cells
did not prevent ceramide generation but inhibited the ability
of exogenous ceramides to activate the distal caspases and to
induce apoptosis, suggesting that Bcl-2 might act downstream
of ceramide formation [5,29,30]. In contrast to Bcl-2, over-
expression of Bcl-xL in MCF-7 cells has recently been found
to interfere with ceramide accumulation and apoptosis in-
duced by tumor necrosis factor-K (TNFK), suggesting that
the action of Bcl-xL might be upstream of the formation of
ceramides [29].
As described above, it is suggested that GSH plays a critical
role in the N-SMase/ceramide pathway. Therefore, it became
important to clarify the relationship between the intracellular
levels of GSH, the Bcl-2 family of proteins and ceramide
generation. Although there are some indications that Bcl-2
and Bcl-xL may function as antioxidants [31^35], it was
shown that Bcl-2 had no e¡ect on intracellular GSH depletion
induced by TNFK in MCF-7 cells [5]. However, the role of
Bcl-xL on this relationship has not yet been determined.
To investigate the relationship between N-SMase, GSH and
Bcl-xL, we examined the e¡ect of Bcl-xL on diamide-, a thiol-
depleting agent, and the TNFK-induced ceramide pathway
using MCF-7 cells expressing Bcl-xL.
2. Materials and methods
2.1. Materials
RPMI 1640, fetal bovine serum (FBS) and trypsin-EDTA were
from Life Technologies. Hygromycin was from Calbiochem. [methyl-
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3H]Choline chloride (1 mCi/ml, 85 mCi/mmol), [Q-32P]ATP (10 mCi/
ml, 3000 Ci/mmol), and EN3HANCE spray were from NEN Life
Science Products. Ceramide type III, bacterial SMase (bSMase)
(from Staphylococcus aureus), GSH, oxidized GSH (GSSG), N-acetyl-
cysteine (NAC), and diamide were from Sigma Chemical Company.
Silica Gel 60 thin-layer chromatography (TLC) plates were from
Whatman. Scintillation mixture Safety Solve was from Research
Products International. All solvents were of AR grade and were
from Mallinckrodt. Glaxo-Smith-Kline Research kindly provided us
with GW69A.
2.2. Cell culture
The previously described cell line overexpressing Bcl-xL was derived
from a TNFK-sensitive MCF-7 parental line [36]. Cells were in RPMI
1640 medium supplemented with 10% FBS. 150 Wg/ml hygromycin
was added to the Bcl-xL cell line and its vector. Experiments were
done in the absence of hygromycin.
2.3. Metabolic labeling of cellular SM
Cells were seeded at 2U105 cells/100-mm Petri dish. After 2 days,
the medium was changed and the cells were labeled with [methyl-
3H]choline chloride (¢nal speci¢c activity: 0.5 WCi/ml) in RPMI
1640/10% FBS for 60 h. Cells were then washed once with phos-
phate-bu¡ered saline (PBS) and chased with RPMI 1640/2% FBS
for 2 h. After washing with PBS again, cells were treated with
0.5 mM diamide or 3 nM TNFK.
2.4. Drug treatment
Prior to 0.5 mM diamide or 3 nM TNFK, cells were incubated in
RPMI 1640/2% FBS containing 100 mU/ml bSMase (for 25 min), 10
WM or 20 WM GW69A (for 45 min), 15 mM GSH (for 2 h) or 10 mM
NAC (for 2 h). The ¢nal concentration of dimethyl sulfoxide (a sol-
vent for GW69A) in the medium was 1.33% (v/v), which has no e¡ect
on cell viability. Each reagent was included in the medium throughout
the subsequent incubations.
2.5. Measurements of [3H]choline-labeled SM
After removing the medium, cells were washed and scraped in PBS.
Cells were pelleted, and total lipids were extracted according to the
Bligh and Dyer method [37]. Total lipid extract was subjected to mild
base hydrolysis [38]. [3H]SM was determined by TLC analysis in
chloroform:methanol:12 mM CaCl2 (90:52.5:12), followed by scrap-
ing and counting the radioactivity by liquid scintillation. SM levels
were determined by measuring the amount (nmol) of inorganic phos-
phate present in the organic phase [39] and were normalized to total
phosphate initially present.
2.6. Ceramide measurements
Cells were seeded at 2U106 cells/100-mm Petri dish in RPMI 1640/
2% FBS, rested overnight, and then treated with 0.5 mM diamide or
3 nM TNFK. Cells were harvested in methanol, and lipids were ex-
tracted using the Bligh and Dyer method [37]. Aliquots of the organic
phase (0.9 ml and 0.3 ml in duplicates) were dried down separately,
and used, respectively, for ceramide and phosphate measurements
[39]. The level of ceramide was determined by the diacylglycerol ki-
nase assay as described [40].
2.7. Measurement of GSH and GSSG levels in cells
Cells were seeded at 2U106 cells/100-mm Petri dish in RPMI 1640/
2% FBS, rested overnight, and then treated with 0.5 mM diamide or
3 nM TNFK. Treated cells were washed with ice-cold PBS, and har-
vested in 3.33% SSA bu¡er (3.33% 5-sulfosalicylic acid, 0.167 mM
EDTA). The supernatant was separated from the acid-precipitated
proteins by centrifugation. GSH and GSSG content in the superna-
tant were determined by the Gri⁄th [41] modi¢cation of Tietze’s
enzymatic procedure [42]. GSH and GSSG content were normalized
to total protein.
3. Results
3.1. Diamide induces the breakdown of SM to ceramide in
MCF-7 cells
First, we investigated the e¡ect of a thiol-depleting agent,
diamide, on intracellular levels of GSH and breakdown of SM
to ceramide in these cells. Diamide is known to reduce acutely
the intracellular levels of GSH by its oxidation to GSSG [43^
45]. Stimulation of MCF-7 cells with 0.5 mM diamide resulted
in an immediate decrease in intracellular levels of GSH
(Fig. 1a) and an increase of the intracellular levels of GSSG
(Fig. 1b). The ratio of GSH/GSSG was therefore signi¢cantly
reduced in diamide-treated cells (Fig. 3c). SM turnover of
approximately 5% could be observed as early as 30 min fol-
lowing treatment of MCF-7 cells with 0.5 mM diamide, and
maximal e¡ects of up to about 20% SM hydrolysis were ob-
served after 60 min of treatment (Fig. 2a). Thus, diamide in-
duces acute hydrolysis of SM.
Next, we determined whether this SM pool hydrolyzed in
response to diamide is on the outer lea£et of the plasma
membrane and accessible to hydrolysis by exogenous SMase.
To this end, cells were treated with bSMase in the presence or
absence of diamide. bSMase induced signi¢cant hydrolysis of
membrane SM (Fig. 2b). However, the e¡ects of diamide were
still observed in the presence of bSMase demonstrating that
the pool of SM hydrolyzed in response to diamide is resistant
to the action of bSMase and suggesting that it may not reside
in the outer lea£et of the plasma membrane (Fig. 2b).
Furthermore, stimulation of cells with 0.5 mM diamide re-
sulted in a time-dependent increase in the production of cer-
amide (Fig. 2c). Taken together, these experiments indicate
that diamide can modulate the breakdown of SM to ceramide
with signi¢cant induction of ceramide production. In addi-
tion, treatment of cells with NAC (10 mM) or extracellular
application of GSH (15 mM) blocked diamide-mediated SM
hydrolysis (Fig. 3a) and ceramide generation (Fig. 3b). These
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Fig. 1. Diamide-induced GSH depletion and GSSG increase in
MCF-7 cells. MCF-7 cells were treated with (closed circles) or with-
out (open circles) 0.5 mM diamide for the indicated times. GSH (a)
and GSSG (b) levels were measured as described in Section 2. Re-
sults are meanQS.D. of three independent experiments.
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results demonstrate that intracellular levels of GSH are im-
portant regulators of breakdown of SM to ceramide.
In order to investigate if these e¡ects are due to activation
of N-SMase, we utilized GW69A, a recently developed speci¢c
inhibitor of N-SMase [46]. GW69A blocked diamide-mediated
SM hydrolysis (Fig. 3a) and ceramide generation (Fig. 3b) but
not diamide-induced reduction of GSH/GSSG ratio (Fig. 3c),
suggesting that the intracellular levels of GSH regulate the
extent to which SM is degraded to ceramide and that this
probably involves a GW69A-sensitive N-SMase.
3.2. Bcl-xL blocks TNFK-induced SM hydrolysis and ceramide
generation at a site downstream of GSH depletion in
MCF-7 cells
Next, we investigated the e¡ects of Bcl-xL on TNFK-in-
duced SM hydrolysis, ceramide accumulation and changes
of GSH levels. First, signi¢cant SM hydrolysis was observed
between 10 and 15 h after treatment with 3 nM TNFK, and a
30% hydrolysis of SM was detected at 15 h (Fig. 4a). How-
ever, Bcl-xL completely inhibited SM hydrolysis. Second,
stimulation of MCF-7 cells with TNFK resulted in a time-
dependent increase in the production of ceramide (Fig. 4b).
Bcl-xL overexpression completely inhibited ceramide accumu-
lation in response to TNFK (Fig. 4c). Third, a time-dependent
depletion of GSH was observed in both wild type and Bcl-xL
cells treated with 3 nM TNFK. These changes were indistin-
guishable from the e¡ects of TNFK in wild type cells (Fig.
4d), suggesting that Bcl-xL does not a¡ect the decrease in
GSH levels in response to TNFK. These results suggested
that Bcl-xL probably acts between the decrease in GSH levels
and generation of ceramide.
3.3. Bcl-xL blocks diamide-induced SM hydrolysis and
ceramide generation at a site downstream of GSH
depletion in MCF-7 cells
The above results suggested that Bcl-xL might act between
the decrease in GSH levels and the breakdown of SM to cer-
amide. To further investigate this possibility, we examined the
e¡ects of Bcl-xL on diamide-induced SM hydrolysis, ceramide
accumulation and changes of GSH levels. First, in the Bcl-xL-
Fig. 2. Diamide-induced SM hydrolysis and ceramide generation in
MCF-7 cells. a: Diamide-induced SM hydrolysis in MCF-7 cells.
Cells were then treated with (closed circles) or without (open circles)
0.5 mM diamide for the indicated time. SM content was analyzed
as described in Section 2. b: Treatment of MCF-7 cells with dia-
mide (for 1 h) and bSMase. Cells were treated with vehicle, 0.5 mM
diamide, 100 mU/ml bSMase, or diamide plus bSMase. Prior to
0.5 mM diamide, cells were incubated in RPMI 1640/2% FBS con-
taining 100 mU/ml bSMase for 25 min. bSMase was included in the
medium throughout the subsequent incubations. c: Lipids were ex-
tracted from cells untreated (open circles) or treated (closed circles)
with 0.5 mM diamide for the indicated time, and ceramide content
was determined as described in Section 2. Results are meanQS.D.
of three independent experiments.
Fig. 3. The e¡ects of GSH, NAC and GW69A on diamide-induced
SM hydrolysis and ceramide generation in MCF-7 cells. a: GSH,
NAC and GW69A inhibit diamide-induced SM hydrolysis. Cells
were treated with or without 0.5 mM diamide for 1 h in the pres-
ence or absence of GW69A, GSH, or NAC. SM content was ana-
lyzed as described in Section 2. b: GSH, NAC and GW69A inhibit
diamide-induced ceramide elevation. Cells were treated with or with-
out 0.5 mM diamide for 1 h, and ceramide content was determined
as described in Section 2. c: The e¡ects of GW69A on diamide-in-
duced reduction of the GSH/GSSG ratio. MCF-7 cells were treated
with (closed circles) or without (open circles) 0.5 mM diamide for
the indicated time. GSH and GSSG levels were measured as de-
scribed in Section 2. Prior to 0.5 mM diamide, cells were incubated
in RPMI 1640/2% FBS with (right panel) or without (left panel) 20
WM GW69A (for 45 min). Results are meanQS.D. of three indepen-
dent experiments.
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transfected cells, a depletion of intracellular GSH and an in-
crease of intracellular GSSG were observed following treat-
ment with 0.5 mM diamide (Fig. 5a^c). These changes were
indistinguishable from the e¡ects of diamide in wild type cells,
suggesting that Bcl-xL does not a¡ect the decrease in GSH
levels in response to diamide. Next, the e¡ects of Bcl-xL on
diamide-induced SM hydrolysis and ceramide generation were
examined. Bcl-xL completely inhibited SM hydrolysis (Fig.
5d) and partially inhibited ceramide generation in response
to 0.5 mM diamide (Fig. 5e). These results suggest that the
site of action of Bcl-xL is downstream of GSH depletion and
upstream of ceramide accumulation, and that Bcl-xL does not
have a major antioxidant function.
4. Discussion
Depletion of endogenous GSH by diamide induces the
breakdown of SM to ceramide, which is blocked by NAC,
GSH and GW69A, suggesting that depletion of GSH is
closely related to regulation of N-SMase activation. Impor-
tantly, the results show that Bcl-xL inhibits diamide-induced
breakdown of SM to ceramide and TNFK-induced ceramide
accumulation, but does not modulate diamide- and TNFK-
induced GSH depletion, suggesting that the site of action of
Bcl-xL is downstream of GSH depletion and upstream of cer-
amide accumulation.
These studies have several interesting and important impli-
cations. First, the current results, showing that diamide in-
duced the breakdown of SM to ceramide, demonstrate that
intracellular levels of GSH and/or reactive oxygen species reg-
ulate the degradation of SM to ceramide. Recent studies have
shown that depletion of intracellular levels of GSH is closely
related to activation of N-SMase and ceramide formation
[5,10^25]. Our results also support these observations. Second,
our results, showing that Bcl-xL and GW69A inhibit the
breakdown of SM to ceramide, but do not modulate the de-
pletion of GSH in response to diamide, support an indirect
mechanism of action for GSH inhibition of N-SMase. These
¢ndings raise the question of what are the mechanisms cou-
pling oxidation/depletion of GSH to the activation of
N-SMase. This may involve undetermined molecule(s) whose
own oxidation may regulate N-SMase. Third, our results
show that Bcl-xL inhibited SM hydrolysis and ceramide accu-
Fig. 4. The e¡ects of Bcl-xL on TNFK-induced SM hydrolysis, cer-
amide elevation, and GSH depletion. a: Bcl-xL inhibits TNFK-in-
duced SM hydrolysis. Bcl-xL- (open circles) or vector- (closed
circles) transfected MCF-7 cells were then treated 3 nM TNFK for
the indicated time. SM content was analyzed as described in Section
2. b,c: Bcl-xL inhibits TNFK-induced ceramide elevation. Bcl-xL-
(c) or vector- (b) transfected MCF-7 cells were treated with (closed
circles) or without (open circles) 3 nM TNFK for the indicated
time, and ceramide content was determined as described in Section
2. d: Bcl-xL has no e¡ect on TNFK-induced GSH. Shown is the
time course for the e¡ect of TNFK on GSH level in Bcl-xL- (trian-
gles) or vector- (circles) transfected MCF-7 cells. Bcl-xL- or vector-
transfected MCF-7 cells were treated with (closed) or without
(open) 3 nM TNFK for the indicated time, and GSH levels were
measured as described in Section 2. Results are meanQS.D. of three
independent experiments.
Fig. 5. The e¡ects of Bcl-xL on diamide-induced SM hydrolysis,
ceramide elevation, and GSH depletion. Bcl-xL-transfected MCF-7
cells were treated with (closed circles) or without (open circles)
0.5 mM diamide for the indicated time. GSH (a) and GSSG (b) lev-
els were measured as described in Section 2. c: The ratio GSH/
GSSG. d: Bcl-xL inhibits diamide-induced SM hydrolysis. Bcl-xL-
(open circles) or vector- (closed circles) transfected MCF-7 cells
were treated with 0.5 mM diamide for the indicated time. SM con-
tent was analyzed as described in Section 2. e: Lipids were extracted
from Bcl-xL- (triangles) or vector- (circles) transfected MCF-7 cells
untreated (open) or treated (closed) with 0.5 mM diamide for the
indicated time, and ceramide content was determined as described
in Section 2. Results are meanQS.D. of three independent experi-
ments.
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mulation in response to diamide and TNFK, and that Bcl-xL
did not block diamide- and TNFK-induced GSH depletion,
suggesting that Bcl-xL acts downstream of the decrease in
GSH levels and that Bcl-xL does not function as a major
antioxidant. The mechanism of action of Bcl-xL remains un-
known, and further investigations are clearly needed to an-
swer this question. Fourth, these results demonstrate a close
relationship between ceramide accumulation, GSH depletion,
and the action of Bcl-xL (Fig. 3). Given the presumed mito-
chondrial site of action of Bcl-2 and its related proteins [47],
they raise an important question as to the subcellular local-
ization of ceramide generation [48,49]. Recent studies have
suggested the presence of ceramide metabolism in mitochon-
dria. Taken together, it is suggested that ceramide might be
generated in mitochondria, and that N-SMase might be local-
ized in mitochondria or in close proximity to mitochondria
(mitochondria-associated membranes).
In conclusion, we have demonstrated that diamide and
TNFK induce the breakdown of SM to ceramide and that
Bcl-xL inhibits this pathway at a site downstream of depletion
of GSH and upstream of ceramide accumulation. The mech-
anism and relevance of the inhibitory action of Bcl-xL on
N-SMase activation should be the subject of future studies.
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